About This EventVanguard, in celebration of their 50th anniversary, visits the Nasdaq MarketSite in Times Square.In honor of the occasion, Joe Davis, Global Chief Economist, rings the Closing Bell.

Palo Alto Networks (PANW) reported its third quarter fiscal 2025 financial results after the bell on Tuesday, which featured ...

About This EventEnact (Nasdaq: ACT) visits the Nasdaq MarketSite in Times Square. Headquartered in Raleigh, NC, Enact is a leading U.S. private mortgage insurance provider committed to helping more ...

ZoomInfo will trade under the Nasdaq symbol GTM starting May 13 ... building the first-ever core software platform for GTM.

Management reported progress in customer trials, with 33 active trials ongoing, including 24 in industrial stages. These trials represent a potential 300 million pounds of product sales ...

8 May 2025, Dubai (UAE): Gulf Islamic Investments (GII), a leading global alternative investment company based in the GCC, was honoured to participate in the iconic Nasdaq bell-ringing ceremony in ...

visits the Nasdaq MarketSite in Times Square. In honor of the occasion, Steve Salis, Chairman & CEO, rings the Closing Bell. Sign up for our newsletter to get the latest on the transformative ...

Palantir Technologies shares are down 11.4% this week. The stock is down despite Palantir delivering solid first-quarter results and lifting its full-year outlook. Discover the top trade setups ...

For Microsoft in the Software industry, the PE and PB ratios suggest that the stock is undervalued compared to its peers. However, the high PS ratio indicates that the stock may be overvalued ...

Management highlighted ongoing progress with STMicroelectronics, focusing on manufacturability and throughput optimization for high-volume production. Weekly meetings and test results indicate a ...

Management reaffirmed the timeline to enroll the additional 30-40 patients in the TakeAim lymphoma study within 12-18 months to support accelerated regulatory filings. The expected responses ...

The company is also advancing a monoclonal antibody IL-1 receptor antagonist dubbed KPL-387 within its pipeline. It is also targeting recurrent pericarditis. KPL-487 is being tested via a monthly ...